Abbott Q2 Sales Rise 13%, Raises Full-Year EPS Guidance on Diagnostics and Device Strength
ABT is trading near its 52-week low of $81.97 (9.8% above the low).
Summary
Abbott reported Q2 2026 sales of $12.6 billion, up 13% reported, with adjusted EPS of $1.31. The company raised its full-year adjusted EPS guidance to $5.45–$5.60 and reaffirmed comparable sales growth of 6.5%–7.5%.
Key Events · Earnings and Guidance · ABT
-
Q2 Sales Up 13% Reported
Total sales reached $12.6 billion, with 4.8% comparable growth. Diagnostics surged 42.3% reported (2.9% comparable) driven by the Exact Sciences acquisition, while Medical Devices grew 9.0% reported (8.4% comparable).
-
Adjusted EPS Beats, Guidance Raised
Adjusted diluted EPS of $1.31 exceeded expectations. Full-year adjusted EPS guidance raised to $5.45–$5.60 from $5.38–$5.58, and Q3 adjusted EPS guided to $1.38–$1.46.
-
Pipeline Milestones Achieved
CE Mark secured for Libre Duo dual glucose-ketone sensor; FDA submission completed for Amulet 360 LAA device; TECTONIC IVL pivotal trial enrollment completed.
-
GAAP EPS Impacted by Acquisition Charges
GAAP diluted EPS was $0.53, reflecting $1.36 billion in after-tax specified items including intangible amortization, acquisition costs, and a $385 million legal reserve.
Analysis · ABT · Life Sciences
Abbott delivered a strong second quarter with 13% reported sales growth, driven by the Exact Sciences acquisition and solid organic performance in Medical Devices and Established Pharmaceuticals. Adjusted EPS of $1.31 beat expectations, and management raised full-year adjusted EPS guidance to $5.45–$5.60, signaling confidence in accelerating momentum through the second half. The quarter also featured notable pipeline progress, including CE Mark for the Libre Duo glucose-ketone sensor and an FDA submission for the Amulet 360 LAA device. While GAAP earnings were weighed down by acquisition-related charges and legal reserves, the underlying business is performing well, and the raised guidance is a clear positive for investors.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABT was trading at $90.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $155.5B. The 52-week trading range was $81.97 to $137.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.